2型糖尿病患者强化降压治疗
该多中心开放标签随机试验在巴西纳入9476例血压升高、2型糖尿病且心血管高危的患者,随机接受强化降压(目标收缩压低于120 mmHg)或标准降压(目标收缩压低于140 mmHg)。随访期间平均收缩压强化组为121.8±10.8 mmHg,标准组为135.4±8.2 mmHg。中位随访4.0年,主要终点事件(心血管死亡、非致死性心肌梗死、非致死性卒中或因不稳定型心绞痛或心力衰竭住院)在强化组发生286例(6.0%),标准组315例(6.7%),HR 0.90(95%CI 0.77-1.06,P=0.20),无显著差异。严重不良事件两组相似(14.9% vs 14.6%)。
要点
- 强化降压目标收缩压低于120 mmHg相比低于140 mmHg未显著减少主要心血管复合终点(HR 0.90,95%CI 0.77-1.06,P=0.20)。
- 随访期间平均收缩压强化组121.8±10.8 mmHg,标准组135.4±8.2 mmHg。
- 严重不良事件强化组706例(14.9%),标准组693例(14.6%),两组相似。
- 该试验纳入9476例2型糖尿病合并心血管高危患者,中位随访4.0年。
适用人群与场景
- 血压升高、2型糖尿病且心血管高危的患者,纳入多中心开放标签随机试验。
处置流程与药物剂量
- 强化治疗组目标收缩压低于120 mmHg,标准治疗组目标收缩压低于140 mmHg。
研究设计与关键结果
- 多中心、开放标签、随机试验,纳入9476例患者,强化组4745例,标准组4731例;平均年龄64.7±8.2岁,女性5871例(62.0%)。
- 随访期间(排除前3个月)平均收缩压强化组121.8±10.8 mmHg,标准组135.4±8.2 mmHg。
- 中位随访4.0年(四分位距3.9-4.0),主要终点事件强化组286例(6.0%;1.65事件/100人年),标准组315例(6.7%;1.83事件/100人年),HR 0.90(95%CI 0.77-1.06,P=0.20)。
- 严重不良事件强化组706例(14.9%),标准组693例(14.6%)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在2型糖尿病合并心血管高危患者中,以收缩压低于120 mmHg为目标的强化降压相比低于140 mmHg未减少主要心血管事件,原文结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Uncertainty persists regarding the effects of intensive blood-pressure lowering in patients with type 2 diabetes.
METHODS: In this multicenter, open-label, randomized trial conducted in Brazil, patients with elevated blood pressure, type 2 diabetes, and high cardiovascular risk received intensive therapy targeting a systolic blood pressure of less than 120 mm Hg or standard therapy targeting a systolic blood pressure of less than 140 mm Hg. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina or heart failure.
RESULTS: Of the 9476 ethnically diverse patients who were enrolled, 4745 were assigned to receive intensive therapy and 4731 to receive standard therapy. The mean (±SD) age was 64.7±8.2 years, and 5871 of the patients (62.0%) were women. The mean systolic blood pressure during follow-up (with exclusion of the first 3 months) was 121.8±10.8 mm Hg in the intensive-therapy group and 135.4±8.2 mm Hg in the standard-therapy group. During a median follow-up of 4.0 years (interquartile range, 3.9 to 4.0), a primary-outcome event occurred in 286 patients (6.0%; 1.65 events per 100 person-years) in the intensive-therapy group and in 315 patients (6.7%; 1.83 events per 100 person-years) in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval, 0.77 to 1.06; P = 0.20). Serious adverse events occurred in 706 patients (14.9%) with intensive therapy and in 693 patients (14.6%) with standard therapy.
CONCLUSIONS: Among patients with type 2 diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the occurrence of major cardiovascular events. (Funded by Hospital Israelita Albert Einstein and the Brazilian Ministry of Health; OPTIMAL-DIABETES ClinicalTrials.gov number, NCT04040634.).
参考来源
- Santo K, Martins E, Silva GS, et al. Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes. N Engl J Med. 2026. PMID: 43001746. doi:10.1056/NEJMoa2612922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。